Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: A multicenter national study by the Greek Myeloma Study Group
Ημερομηνία
2018Γλώσσα
en
Λέξη-κλειδί
Επιτομή
We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based combinations; 40% underwent autologous stem cell transplantation (ASCT). Objective response rate was 76; 38% achieved at least very good partial response (≥vgPR) and this correlated significantly with bortezomib-based therapy plus ASCT. At the time of evaluation, 40 patients had died. Early mortality rate (≤1 month) was 6%. Median progression-free survival (PFS) and overall survival (OS) were 12 months and 18 months respectively, both significantly longer in patients treated with bortezomib-based therapy + ASCT vs. others (PFS: 18 vs. 9 months; p = 0.004, OS: 48 vs. 14 months; p = 0.007). Bortezomib-based therapy + ASCT predicted for OS in univariate analysis. In multivariate analysis, achievement of ≥vgPR and LDH ≥ 300 U/L were significant predictors for OS. These real-world data, based on one of the largest reported national multicenter series of pPCL patients treated mostly with novel agents support that, among the currently approved induction therapies, bortezomib-based regimens are highly effective and reduce the rate of early mortality whereas in combination with ASCT consolidation they prolong OS. © 2018 The Author(s).
Collections
Related items
Showing items related by title, author, creator and subject.
-
Prognostic significance of flow cytometry MRD log reduction during induction treatment of childhood ALL
Ampatzidou M., Paterakis G., Vasdekis V., Papadhimitriou S.I., Papadakis V., Vassilopoulos G., Polychronopoulou S. (2019)[No abstract available] -
In silico methods for the identification of diagnostic and favorable prognostic markers in acute myeloid leukemia
Yılmaz H., Toy H.I., Marquardt S., Karakülah G., Küçük C., Kontou P.I., Logotheti S., Pavlopoulou A. (2021)Acute myeloid leukemia (AML), the most common type of acute leukemia in adults, is mainly asymptomatic at early stages and progresses/recurs rapidly and frequently. These attributes necessitate the identification of ... -
HDAC7 is a major contributor in the pathogenesis of infant t(4;11) proB acute lymphoblastic leukemia
de Barrios O., Galaras A., Trincado J.L., Azagra A., Collazo O., Meler A., Agraz-Doblas A., Bueno C., Ballerini P., Cazzaniga G., Stam R.W., Varela I., De Lorenzo P., Valsecchi M.G., Hatzis P., Menéndez P., Parra M. (2021)[No abstract available]